Our findings demonstrated that simultaneous inhibition of EGFR and α5β1 integrin activation and signaling led to an overall decrease in VM and tumor cell motility in vitro and tumor growth and metastasis in vivo. The gene discussed is EGFR; the disease is neoplasm.